GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » YoY Rev. per Sh. Growth

Collegium Pharmaceutical (Collegium Pharmaceutical) YoY Rev. per Sh. Growth : -37.12% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Collegium Pharmaceutical's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 was -37.12%.

Collegium Pharmaceutical's Revenue per Share for the three months ended in Dec. 2023 was $2.43.

Collegium Pharmaceutical YoY Rev. per Sh. Growth Historical Data

The historical data trend for Collegium Pharmaceutical's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical YoY Rev. per Sh. Growth Chart

Collegium Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.23 -0.55 -23.53 103.32 -1.10

Collegium Pharmaceutical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 469.32 69.60 -12.96 -11.54 -37.12

Collegium Pharmaceutical YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Collegium Pharmaceutical's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(13.563-13.714)/ | 13.714 |
=-1.10 %

Collegium Pharmaceutical's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2023 )
=(Revenue per Share (Q: Dec. 2023 )-Revenue per Share (Q: Dec. 2022 )) / | Revenue per Share (Q: Dec. 2022 )) |
=(2.427-3.86)/ | 3.86 |
=-37.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Collegium Pharmaceutical YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Collegium Pharmaceutical (Collegium Pharmaceutical) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
AVDL AMRX DCPH PETQ HROW PAHC EOLS SIGA PROC BKUH ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
354:Germany
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Website
https://www.collegiumpharma.com
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.
Executives
Scott Dreyer officer: EVP & Chief Commercial Officer 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Joseph Ciaffoni director, officer: President and CEO 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Shirley R. Kuhlmann officer: EVP and General Counsel 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Tupper Colleen officer: EVP & Chief Financial Officer C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Rita J. Balice-gordon director C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Thomas B Smith officer: EVP and Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Richard Malamut officer: EVP and Chief Medical Officer 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming officer: Vice President, Product Devlp 780 DEDHAM STREET, SUITE 800, CANTON MA 02021